head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2020, vol. 26, issue1
Subject Area: Medicine
DOI: 10.5272/jimab.2020261.2905
Published online: 12 February 2020

Original article

J of IMAB. 2020 Jan-Mar;26(1):2905-2909
Vanya Slavcheva1ORCID logo Corresponding Autoremail, Georgi Balatzenko2ORCID logo, Svetlana Angelova2ORCID logo, Emilia Naseva3ORCID logo, Tzvetan Lukanov4ORCID logo, Nikolai Tzvetkov1ORCID logo,
1) Clinic of Haematology, University Hospital, Medical University, Pleven, Bulgaria.
2) National Hematological Hospital, Lab of cytogenetics and molecular biology, Sofia, Bulgaria.
3) Department of Health Economics, Faculty of Public Health, Medical University, Sofia, Bulgaria.
4) Immunological laboratory, University Hospital, Medical University, Pleven, Bulgaria.

Aim: Chronic lymphocytic leukaemia (CLL) is one of the most common leukaemias in adults. Unlike myeloid and acute lymphoblastic leukaemia, treatment can be delayed after diagnosis. Exploration of the unique biology of the disease has led to the identification of more than 35 prognostic factors reported in the literature. In practice, however, the number of validated clinical and biological prognostic factors is significantly smaller. The purposes of our study are: to investigate the distribution of untreated CLL- patients according to Binet staging as well as to analyse the frequency of one of the most common chromosomal aberrations in the group. To study  the correlation between mutational status (determined by evaluation of lipoprotein lipase/ ADAM29 ratio), and the identified chromosomal aberrations in the group of 48 untreated patients.
aterials and methods: We studied 48 patients with a confirmed flowcytometric diagnosis B-CLL, using the 2008 IWCLL-NCI criteria.  The interphase fluorescence in situ hybridization (FISH) was applied to determine the chromosomal abnormalities. Analysis of mutational status was performed as described by Pablo Oppezzo with slight modification. Documentary and statistical methods were used for data processing by Fisher`s Exact test.
Conclusion: We found that a large proportion of patients were diagnosed with early-stage A of the disease. In most untreated CLL- patients  isolated del13q was detected. Statistically, a significant association was found between del13q, del11q, del17p / p53 and mutational status.

Keywords: lymphocytic leukaemia, lipoprotein lipase, ADAM29, del13q14, prognosis,

pdf - Download FULL TEXT /PDF 682 KB/
Please cite this article as: Slavcheva V, Balatzenko G, Angelova S, Naseva E, Lukanov Tz, Tzvetkov N. Clinical study of gene expression profile and some of the most common chromosomal aberrations in untreated B-chronic lymphocytic leukaemia patients. J of IMAB. 2020 Jan-Mar;26(1):2905-2909.
DOI: 10.5272/jimab.2020261.2905

Corresponding AutorCorrespondence to: Vanya Slavcheva, MD. Clinic of Hematology, University hospital, Medical University Pleven; 8 A, G. Kochev blvd., Pleven 5800, Bulgaria; E-mail: slavcheva05@gmail.com

1. Miranda-Filho A, Pineros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018 Jan;5(1):e14-e24. [PubMed] [Crossref]
2. Slager SL, Caporaso NE, de Sanjose S, Goldin LR. Genetic susceptibility to chronic lymphocytic leukemia. Semin Hematol. 2013 Oct;50(4):296-302. [PubMed] [Crossref]
3.Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Jan 19;3:16096. [PubMed] [Crossref]
4.Karan‐Djurasevic T, Pavlovic S. Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in Chronic Lymphocytic Leukemia. In: Lymphocyte Updates - Cancer, Autoimmunity and Infection. Edited by Isvoranu G. IntechOpen. July 12th 2017. Chapter 3. 864.  [Crossref]
5.Del Poeta G, Dal Bo M, Buccisano F, Pozzo F, Del Principe MI, Bulian P, et al. Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). Blood. 2015 Dec;126(23):1718. Poster. [Crossref]
6trati P, Jain N, O'Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 2018 May;93(5):651-664. [PubMed] [Crossref]
7.Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? J Clin Oncol. 2014 Mar 20;32(9):869-72. [PubMed] [Crossref]
8. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. (GCLLSG). Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 2002 Jun;16(6):993-1007. [PubMed] [Crossref]
9. Baliakas P, Iskas M, Gardiner A, Davis Z, Plevova K, Nguyen-Khac F, et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol. 2014 Mar;89(3):249-55. [PubMed] [Crossref]
10. Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood. 2005 Jul 15;106(2):650-7. [PubMed] [Crossref]
11. Campo E, Cymbalista F, Ghia P, Jager U, Pospisilova S, Rosenquist R, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018 Dec;103(12):1956-1968. [PubMed] [Crossref]
12. Shkavrova TG, Mikhailova GF, Goloub EV, Tsepenko VV, Danilenko AA, Pavlov VV. [Molecular cytogenetic follow-up of chronic lymphocytic leukemia patients with unfavorable prognosis.] [in Russian] Oncohematology. 2016; 11(2):30-36.  [Crossref]
13. Gaidano G, Foа R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012 Oct;122(10):3432-8. [PubMed] [Crossref]
14. Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program. 2006:279-84. [PubMed] [Crossref].
15.Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, et al. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2011 Aug;50(8):633-43. [PubMed] [Crossref]
16rlandi EM, Bernasconi P, Pascutto C, Giardini I, Cavigliano PM, Boni M, et al. Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH. Hematol Oncol. 2013 Sep;31(3):136-42. [PubMed] [Crossref]
17. Nedeva A, Naseva E, Kindekov I, Petkova N, Nikolov I, Raynov J. The prognostic significance of interphase cytogenetic abnormalities in chronic lymphocytic leukemia. Arch Hellen Med. 2018 Jul-Aug;35(4):520-526.
18.Gelenis D,  Samir D, Julio C,  Estrella C,  Paibel A,  Kendra S, et al. Impact of immunoglobulin heavy chain variable region mutational status on the outcome of patients with chronic lymphocytic leukemia harboring isolated 13q deletion. ASCO Meeting Abstracts. (2012). 30. 6608.
19ozovski U, Keating MJ, Estrov Z. Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia? Acta Haematol. 2018; 140(1):51-54. [PubMed] [Crossref]
20. Eagle GL, Zhuang J, Jenkins RE, Till KJ, Jithesh PV, Lin K, et al. Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia. Mol Cell Proteomics. 2015 Apr;14(4):933-45. [PubMed] [Crossref]
21 Prieto D, Oppezzo P. Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression. Molecules. 2017 Dec 5;22(12). pii:E2083.
[PubMed] [Crossref]
22. Hartman M, Kilianska Z. Lipoprotein lipase: anew prognostic factor in chronic lymphocytic leukaemia Wspolczesna Onkol 2012; 16 (6): 474–479
23. Lopez C, Delgado J, Costa D, Villamor N, Navarro A, Cazorla M, et al. Clonal Evolution in Chronic Lymphocytic Leukemia: Analysis of Correlations With IGHV Mutational Status, NOTCH1 Mutations and Clinical Significance. Genes Chromosomes Cancer. 2013 Oct;52(10):920-7. [PubMed] [Crossref]
24. Molecular Pathology with Online Resource: A Practical Guide for the Surgical Pathologist and Cytopathologist. Edited by: Bartlett JMS, Shaaban A, Schmitt F. 1st edition. Cambridge University Press. February 1, 2016. pp.414. [Internet].

Received: 10 June 2019
Published online: 12 February 2020

back to Online Journal